Colleen Kusy

Stock Analyst at Baird

(1.66)
# 3,425
Out of 5,154 analysts
52
Total ratings
35.56%
Success rate
-0.84%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Colleen Kusy

Climb Bio
Mar 6, 2026
Maintains: Outperform
Price Target: $9$12
Current: $7.18
Upside: +67.13%
argenx SE
Feb 27, 2026
Maintains: Neutral
Price Target: $858$867
Current: $717.79
Upside: +20.79%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112$158
Current: $99.41
Upside: +58.94%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14$34
Current: $37.08
Upside: -8.31%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50$52
Current: $20.07
Upside: +159.09%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17$24
Current: $10.27
Upside: +133.69%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40$52
Current: $29.44
Upside: +76.63%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4$6
Current: $2.96
Upside: +102.70%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37$41
Current: $26.96
Upside: +52.08%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4$6
Current: $1.82
Upside: +229.67%
Maintains: Outperform
Price Target: $50$65
Current: $40.15
Upside: +61.89%
Reiterates: Outperform
Price Target: $27$25
Current: $13.71
Upside: +82.35%
Maintains: Outperform
Price Target: $255$210
Current: $8.77
Upside: +2,294.53%
Maintains: Outperform
Price Target: $30$34
Current: $5.13
Upside: +562.77%
Initiates: Outperform
Price Target: $230
Current: $3.79
Upside: +5,968.60%